Market Place
Sourcing Support
ImPact Biotech Presents Updated Padeliporfin VTP Data at AUA 2025
28 Apr 2025 //
GLOBENEWSWIRE
ImPact Biotech Presents New Data on Padeliporfin VTP at AUA 2025
11 Apr 2025 //
GLOBENEWSWIRE
ImPact Biotech Announces 50% Enrollment In Phase 3 Englighted Trial
27 Sep 2024 //
GLOBENEWSWIRE
ImPact`s Padeliporfin VTP Data In Low Grade Upper Tract Urothelial Cancer
02 Jun 2024 //
GLOBENEWSWIRE
ImPact`s Padeliporfin Shows Positive Phase 3 Bladder Cancer Data
06 May 2024 //
GLOBENEWSWIRE
ImPact Biotech`s Padeliporfin VTP UTUC Data at Conferences
24 Apr 2024 //
GLOBENEWSWIRE
ImPact Biotech Receives FDA Clearance of IND Application for Padeliporfin
20 Dec 2023 //
GLOBENEWSWIRE
ImPact Biotech receives FDA Clearance for Padeliporfin VTP Phase 1 Program
04 Aug 2023 //
GLOBENEWSWIRE
ImPact Biotech receives FDA Orphan Drug Designation for Padeliporfin
05 Jul 2023 //
GLOBENEWSWIRE
FDA Granted Orphan Drug Designation to Novel ImPACT Agent
08 Mar 2021 //
TARGETEDONC
FDA Grants Fast Track Designation to Padeliporfin ImPACT for Steba biotech
15 Jan 2021 //
PRNEWSWIRE
NICE says Tookad too expensive for prostate cancer
03 Jul 2018 //
PHARMA TIMES
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.